🇺🇸

Index Intelligence

· daily

S&P 500 Energy Sector SEC Filings — March 20, 2026

Filings from the S&P 500 Energy stream reveal a mix of capital raising initiatives and modest operational updates in energy-adjacent sectors like oil tankers, with Okeanis Eco Tankers reporting a slight 0.4% YoY revenue decline to $391.5M for 2025 despite 1.3% TCE growth to $265.4M driven by 1.4% higher operating days at 5,025. Papa Medical's S-1/A signals IPO readiness with $15M gross proceeds targeted at $4/share, underscoring funding for hemp-derived products potentially tied to energy-alternative markets. Bioxytran completed a $1.2M private placement at $0.055/share, issuing 21M shares and warrants, reflecting positive sentiment amid working capital needs. AParadise Acquisition Corp.'s 425 filing promotes a SPAC merger with Enhanced Games, highlighting a May 24, 2026 catalyst event amid regulatory shift hopes for peptides. Portfolio-level trends show 1/4 filings with YoY revenue contraction (Okeanis -0.4%), but positive capital inflows averaging ~$10M+ per issuance; mixed sentiments dominate (50% mixed), with new issuances bullish. Key implication: Energy services face flat TCE rates (-0.1% YoY at $52,823), pressuring margins, while SPACs and placements offer entry points ahead of catalysts.

3 high priority 1 medium 4 total filings
· daily

S&P 500 Financials Sector SEC Filings — March 20, 2026

Across 50 SEC filings from diverse sectors (despite Financials stream focus, data spans tech, health, retail, SPACs), mixed sentiment prevails in 70% of material filings (>5/10), with 12/20 10-Ks showing revenue growth averaging 72% YoY (e.g., Firefly +163%, Aeva +99%, Belpointe +244%) but net losses widening in 8/12 by avg 55% YoY due to op ex surges and impairments. Margin expansions noted in 5 cos (QIAGEN +1339bps gross, Latham +320bps, Dollar General +107bps), contrasting compression elsewhere; M&A/SPAC activity peaks with Embecta/Pelican deals closing soon, Prestige accretive acq. Capital allocation lean: News Corp $1B buyback ongoing, limited dividends/insider trades (no major buys/sells flagged). Proxy season ramps with 15+ AGMs Apr-May 2026 as catalysts; Financials-specific: Civista Q1 earnings Apr22, Metro Bank AI push/headcount +10%. Portfolio implication: Favor rev accelerators with margin inflection (Dollar General, Latham) over loss-makers; watch SPAC redemptions (Pelican 63%) for dilution risks.

34 high priority 16 medium 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — March 20, 2026

Across the 8 S&P 500 Technology stream filings, dominant themes include robust revenue growth in core software players like Snowflake (29% YoY to $4.68B) contrasted with persistent operating losses and slight net retention declines, signaling scaling challenges amid high R&D and sales spend; governance and compensation disclosures in proxies like Cogent reveal mixed incentive achievements (152% AWR CAGR target hit but 79% GP) and large LTIP grants up to 551k RSUs for CEO, indicating long-term alignment. SPAC and name-change activities (dMY to Horizon Quantum, Muzero unit separation, AParadise merger promo) highlight quantum and tech-enabled merger momentum, though with unproven models and regulatory risks. Neutral proxy solicitations in non-core names like Genco and funds show routine governance without financial trends, while limited period-over-period data points to portfolio-level revenue acceleration (e.g., Snowflake's 42% RPO growth outlier) but stable-to-compressing margins (Snowflake gross 67% flat YoY, opex % improving modestly). Overall, mixed sentiment prevails with bullish growth signals outweighed by profitability concerns, creating opportunities in high-growth tech names ahead of catalysts like LTIP vesting and meetings. Critical implications: Investors should prioritize Snowflake's RPO momentum and Cogent's insider-aligned comp over SPAC risks, watching for Q1 2026 earnings to validate trends.

5 high priority 3 medium 8 total filings
· daily

Nasdaq 100 Stocks SEC Filings — March 20, 2026

Across 12 NASDAQ-100 related filings from March 20, 2026, proxy season dominates with 5 DEF/DEFA14A filings signaling imminent annual meetings and governance focus, while financial disclosures reveal mixed period-over-period trends: Zegna's FY2025 revenue declined 1.5% YoY to €1,917M but profit surged 20.5% YoY to €109M on 90 bps gross margin expansion; IPM reported FY2025 revenue of $23.6M with net loss down 42% YoY and Q4 Adjusted EBITDA turning positive post-transformation. Positive highlights include Gilead's robust HIV/oncology pipeline with up to 7 launches by 2033 and bulevirtide potential in 2026, AITX's new AI security order, and IPM's accretive acquisition adding 17k customers. Critical risks emerge in Faraday Future's Nasdaq delisting notice for sub-$1 bid price, granting 180 days to September 16, 2026, compliance. Portfolio-level patterns show profitability resilience amid revenue softness in luxury/shipping, SPAC liquidity/m erger progress, and limited insider details but LTIP grants signaling long-term alignment in Cogent/Gilead. Actionable implications favor monitoring pharma catalysts and avoiding delisting risks, with capital allocation tilting toward acquisitions/RSUs over dividends.

6 high priority 6 medium 12 total filings
· daily

Dow Jones 30 Stocks SEC Filings — March 20, 2026

Across the 50 SEC filings from the USA Dow Jones 30 intelligence stream (primarily blue-chip adjacent with diverse small/mid-caps), financial performance is mixed: 14/25 annual reports (10-K/20-F) show revenue growth averaging +35% YoY (outliers like Aeva +99%, Yellowstone +52%), but 11 report declines averaging -15% YoY (e.g., Urban One -16.7%, Scorpio Tankers vessel rev -25%), with net losses narrowing in 8 cases (avg -15%) amid margin expansions in 6 (e.g., QIAGEN +1330 bps to 62.2%). M&A activity surges with 4 deals (KORE $9.25/share cash merger, Kennedy-Wilson merger, Stock Yards/Field & Main 0.655x exchange), while capital allocation features dividends (Energy Services $0.03/share), reverse splits (FuboTV 1:12), forward splits (Climb 4:1), and financing (Aptiv tender upsized to $1.371B). Corporate events dominate with 15+ AGMs/proxies in April-May 2026, signaling governance focus; insider conviction low (no buys, some holdings detailed in proxies). Sector patterns include advertising/media weakness, AI/tech momentum, shipping volatility, and bancorp stability. Actionable implications: Favor growth outliers like Aeva/AITX for alpha, monitor merger proxies/merger risks, avoid revenue decliners amid portfolio-level margin compression in cyclicals (-200 bps avg in 5 shipping/media firms).

30 high priority 20 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 20, 2026

Across the 50 filings in the S&P 500 Consumer Discretionary stream (with broader exposure via SPACs, M&A targets, and adjacents), overarching themes include robust revenue growth in high-flyers like Firefly Aerospace (+163% YoY), FiEE (+868% YoY), and Snowflake (+29% YoY), contrasted by margin pressures and widening losses in scaling firms (e.g., AutoZone op profit -1.2% YoY, Scorpio Tankers net income -49% YoY). Retail standouts like Dollar General showed resilient +5.2% sales growth and +107 bps gross margin expansion, while capital allocation leaned toward buybacks ($250M at First Industrial, AutoZone $742M) and dividends (Energy Services $0.03/share). M&A activity surged with UniFirst-Cintas deal (H2 2026 close) and NSA-Public Storage, signaling consolidation; insider moves were muted but resignations prevalent (e.g., FIS CTO, Lifeward director). Portfolio-level trends: 12/20 revenue reporters posted >20% YoY growth (avg +150%), but 8/15 profitability metrics declined (avg net income -15%), with mixed sentiment (22 mixed, 10 positive). Forward catalysts cluster in Apr-May AGMs; watch Nasdaq compliance risks in Lifeward/FFIE. Implications: Tactical buys in growth retail/tech, caution on overlevered cyclicals amid mixed guidance.

38 high priority 12 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — March 20, 2026

Across 29 filings in the USA S&P 500 Healthcare stream (with broader cross-sector context), dominant themes include the onset of 2026 proxy season with 15+ annual meetings clustered April-May, robust period-over-period profitability gains in select names (e.g., Eli Lilly $65.2B revenue, Spruce Biosciences net loss improved 26% YoY to $39M, Heritage Financial net income +56% YoY), and healthcare-specific catalysts like Gilead's pipeline advancements (7 HIV launches by 2033, bulevirtide 2026), Eli Lilly's superior Zepbound data (20.2% weight loss vs Wegovy 13.7%), Exact Sciences/Abbott merger closing March 23, and Artelo Biosciences' compelling Phase 2a trial (6.38% weight gain vs placebo loss). Margin trends mixed: expansions in Zegna (+90 bps gross to 67.5%) and Ameriprise (+40 bps adjusted to 26.9%) offset by compressions elsewhere (Zegna op margin -130 bps to 7.3%, Spruce G&A +16% YoY). Capital returns strong in financials (Ameriprise $3.4B +20% YoY, News Corp $1B repurchase), biotech financing mixed (Cingulate dilution risk from $25M facility, Spruce $50M loan). Healthcare outliers show pipeline conviction (Gilead, Lilly, Artelo positive sentiment 8-9/10 materiality) amid Nasdaq compliance risks (Lifeward negative 9/10). Portfolio implication: overweight pharma/biotech on catalysts, monitor governance votes and M&A closes for near-term volatility.

13 high priority 16 medium 29 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — March 19, 2026

Across 50 filings in the USA S&P 500 Consumer Staples stream (though diverse with funds, biotechs, REITs), proxy statements dominate (24/50, neutral sentiment) signaling robust governance ahead of clustered April-May 2026 annual meetings. Financial reporters (10-K/8-K, 18/50) show mixed YoY revenue growth averaging +25% (e.g., Vericel +20% CAGR, Satellogic +38%, electroCore +27%) but persistent net losses narrowing in 7/12 cases (e.g., SentinelOne op inc positive swing). Margin trends mixed with expansions (Signet adj op inc +3.4% FY, Vericel gross 74%) offset by compressions (Signet Q4 -60bps). Capital allocation leans positive: dividend hikes (Signet +17% to $0.35/sh, Modiv $0.10/mth), buybacks (Mount Logan $10M program), accretive M&A (Mount Logan +30% FRE). Forward guidance cautious (Signet FY27 SSS -1.25% to +2.5%) amid Q4 softness, but clinical catalysts in biotechs. Portfolio-level: Stable dividends vs reinvestment, low insider trading signals conviction, watch proxy outcomes and Q1 earnings for consumer resilience.

29 high priority 21 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — March 19, 2026

Across 50 filings in the USA S&P 500 Industrials stream (broadly including transportation, construction, and adjacent sectors amid mixed data), overarching themes include robust revenue growth in transportation leaders like FedEx (+8% YoY Q3 to $24B) and strategic pivots (UPS prioritizing high-value volume), contrasted by widening losses in biotechs (Eledon +26% net loss YoY) and operational declines (Gemini trading volume -30% QoQ). Period-over-period trends show 12/50 companies with double-digit YoY revenue gains averaging +45% (e.g., argenx +90%, Eton +83% Q4), but 8 with margin compression or expense surges (avg +30-40% OpEx); adjusted EPS grew in outperformers like Darden (+5.4%) and FedEx (+16.4%). Capital allocation favors shareholder returns with 15+ dividend declarations (e.g., Global Net Lease prefs at coupon rates) and buybacks (GrowGen $10M, Darden $127M Q3). Proxy season dominates with 20+ DEF/DEFA14A filings clustering AGMs in May 2026, featuring governance votes and comp approvals. Forward-looking signals positive: FedEx raised FY26 guidance (rev 6-6.5%, EPS $19.30-20.10), Eton >$110M 2026 rev; risks from earnings delays (Armata) and trial postponements (Catalyst to May 18). Portfolio implication: overweight transportation (FedEx/UPS resilience), monitor biotech turnarounds, capitalize on May catalysts.

24 high priority 26 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — March 19, 2026

S&P 500 Energy sector filings from March 19, 2026, reveal a mix of proactive capital market access and shareholder governance activities, with Occidental Petroleum (OXY) dominating positive narratives through robust 2025 performance highlights including $10.5B operating cash flow, $4.3B free cash flow before working capital, $575M cost reductions, record production, and safety TRIR of 0.07 despite YoY challenging commodity prices. Cheniere Energy (LNG) signals strong liquidity via $1.75B senior notes issuance (5.200% due 2036, 6.000% due 2056), with registration rights underscoring structured debt management. Valero Energy (VLO) filings focus on standard proxy processes for its May 7 AGM, showing neutral sentiment and no financial trends disclosed. Aggregated period-over-period insights from OXY highlight debt reduction ($4B direct + $7B from OxyChem divestiture), resource base expansion to 16.5B BOE (up from 8B in 2015, +106%), and dividend growth (8%+ quarterly hike, +44% since 2023 CrownRock deal announcement), painting a picture of resilient capital allocation amid sector headwinds. Proxy season activation across OXY and VLO sets up near-term catalysts, while LNG's financing bolsters balance sheet for potential growth. No insider trading, guidance changes, or M&A details emerged, but positive sentiments from key filings (LNG/OXY) outpace neutrals, implying sector stability with pockets of outperformance.

3 high priority 2 medium 5 total filings
· daily

S&P 500 Financials Sector SEC Filings — March 19, 2026

Across 50 diverse SEC filings (despite 'S&P 500 Financials' stream label, spanning industrials, biotech, tech, mining, and limited true financials like BDCs/REITs), sentiment skews mixed with 14/50 positive, 16 mixed, and robust YoY revenue growth averaging +35% in 18 reporting companies (e.g., Micron +196%, Cardinal +45%, SUNation +26%) offset by declines in 6 (e.g., Solo Brands -30%, DarioHealth -17%). EBITDA/margin expansions prevalent in 12 cases (e.g., SUNation + to $2.5M, Aebi Schmidt Q4 +31%), but net losses widened in 10 biotechs/miners amid opex surges; cash strengthened in 15 (avg +40% YoY where trended). Capital allocation favors dividends (8 declarations steady, e.g., Chicago Atlantic BDC $0.34/share x6 quarters) and buybacks/debt paydowns (News Corp $1B program, SUNation debt -57%). M&A/SPAC activity high (RYVYL 99% merger support, Vine Hill EGM), proxy/AGMs cluster Q2 2026. Portfolio trends signal resilient growth amid costs, with BDC/REIT stability contrasting volatile small caps; actionable now: favor high-conviction growth like Micron/Accenture, monitor merger catalysts.

23 high priority 27 medium 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — March 19, 2026

Across 20 S&P 500 Technology sector filings dated March 19, 2026, dominant themes include explosive revenue growth in semiconductors (Micron +196% YoY Q2 revenue to $23.9B) contrasted with modest IT services expansion (Accenture +8.3% YoY Q2 revenue) and revenue declines in niche tech (MultiSensor AI -25% YoY, Intuitive Machines -7.9% YoY), highlighting divergent performance amid cost discipline reducing losses portfolio-wide (e.g., Mustang Bio net loss -88% YoY, MultiSensor AI -46% YoY). Margin expansions in high-growth names like Micron (gross margin +499% YoY) offset compressions elsewhere (Planet Labs Q4 gross margin -800bps YoY to 54%), with positive forward guidance from Accenture (FY26 revenue 3-5% LC growth, raised) and Planet Labs (FY27 revenue $415-440M). Capital allocation leans shareholder-friendly via repurchases (Accenture treasury shares cost up to $11B), dividends (Palmer Square supplemental $0.01/share, Community Bancorp $0.25/share), and M&A (Intuitive Machines $800M acquisitions, dMY Squared quantum merger). Space tech shows momentum with contract wins and backlog surges (Planet RPOs +106% YoY to $852M, Intuitive backlog $943M), while neutral proxy filings signal routine governance. Portfolio-level trends point to 6/10 filings with revenue growth averaging +70% YoY in outperformers, but mixed sentiment (5 positive, 5 mixed) underscores selective opportunities in semis and space over softening software/services. Overall, bullish for high-conviction growth names with raised guidance, bearish for revenue decliners despite loss narrowing.

10 high priority 10 medium 20 total filings
· daily

Nasdaq 100 Stocks SEC Filings — March 19, 2026

Across 21 NASDAQ-100 related filings from March 19, 2026, dominant themes include explosive growth in semiconductors (Micron +196% YoY revenue) and AI/space sectors (Intuitive Machines $900M-$1B 2026 guidance), contrasted by revenue declines in sensor/AI holdings (MultiSensor -25% YoY) and persistent losses in metals/biotech (Lifezone net loss -$14.1M). Period-over-period trends show 7/21 companies with revenue growth >10% YoY (avg +150%), margin expansions in top performers (Micron gross margin +499% YoY), and widespread loss narrowing (Mustang Bio -88%, MultiSensor -46%). Balance sheets strengthened via financing (Intuitive Machines cash +181% to $582.6M, MultiSensor +459% to $24.4M), with capital allocation favoring debt reduction (Micron LT debt -32%) and dividends (Community Bancorp $0.25/share). Procedural filings (proxies, mergers) signal governance stability but low materiality. Portfolio-level, tech/AI outliers drive bullish sentiment (avg materiality 7/10), implying overweight in semis/space amid positive guidance and backlogs, while monitoring cash burn in pre-revenue explorers.

12 high priority 9 medium 21 total filings
· daily

Dow Jones 30 Stocks SEC Filings — March 19, 2026

Across 50 filings from the USA Dow Jones 30 intelligence stream (primarily smaller caps and blue-chips like UPS, CVS), a mixed sentiment prevails with 12/50 showing positive revenue/EBITDA growth (avg +40% YoY where reported, e.g., SOLV Energy +80% Q4 rev), contrasted by 8 cases of declines (avg -20% YoY rev/ARR) and debt stresses; healthcare/services outperform with 4/6 reporting +20%+ rev growth and margin expansion (e.g., Vericel 74% gross margin, +33% Adj EBITDA). Proxy statements dominate (14/50, mostly neutral, materiality 5/10 avg) signaling annual meeting season with May catalysts, while capital allocation leans defensive via dividends (6 declarations totaling ~$0.40-0.46/share quarterly). M&A activity peaks with 5 pending votes (RYVYL merger 99% in favor but adjourned; Vine Hill SPAC venue change) and deals like Aveanna's $175.5M acquisition. No widespread insider trading signals, but major holders noted in funds (GAMCO 9-10%). Forward guidance bullish for 7 cos (e.g., SOLV $3.72-3.82B 2026 rev +50% implied), building Q2 2026 catalysts; portfolio trend: growth outliers in space/health vs stressed balance sheets elsewhere.

29 high priority 21 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 19, 2026

Across 50 SEC filings from the USA S&P 500 Consumer Discretionary stream (broadly encompassing retail, logistics, services), proxy season dominates with 20+ DEF 14A/DEFA14A filings for AGMs clustered in April-May 2026, emphasizing board elections, say-on-pay, and auditor ratifications amid neutral sentiment. Financial performance is polarized: standout YoY revenue growth in retail/logistics (Five Below +22.9% to $4.76B, FedEx Q3 +8% to $24B, Firefly Aerospace +163% to $159.9M) and industrials (Cardinal Infrastructure +45% to $456M, York Space +52% to $386M), contrasted by declines (FiscalNote FY25 -21% to $95.4M, Crawford -2.3% to $1.31B) and widening losses (Larimar Q4 $62.5M vs prior $28.8M). Capital allocation trends positive with buybacks (Aflac $3.5B/33M shares, Crawford $10.5M up from $3.9M), dividend hikes (Aflac +5.2% to $0.61 Q1 2026, Crawford +3.6% to $0.29), and debt reductions (Crawford -24.8% to $151M, Wolfspeed refinancing $475.9M higher-cost notes). Forward guidance largely raised/affirmed (FedEx FY26 rev growth to 6-6.5%, Firefly $420-450M, Cardinal 20%+ EBITDA margin), signaling resilience in consumer demand despite margin pressures (e.g., Cardinal gross margin -80bps to 14%). M&A/JV activity bullish (UniFirst-Cintas merger, Horizon $100M JV), with no notable insider transactions but major holders like GAMCO/Saba in funds. Portfolio-level: 8/15 key financial filers show >20% rev growth avg +60%, but 5 report margin compression avg -100bps; actionable now on catalysts like FedEx spin-off.

27 high priority 23 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — March 19, 2026

Across 45 filings in the USA S&P 500 Healthcare stream, biotech and healthcare firms (e.g., Assembly, SELLAS, Humacyte, Inhibrx) dominate with narrowed net losses (avg -20% YoY across 6 biotechs) amid R&D ramps (+16% avg YoY) and key partnerships like Gilead's $35M HPI license to Assembly, but cash burns persist requiring shelf registrations and offerings. Broader filings reveal mixed revenue trends (+1.6% YoY sales at Signet, -5.5% at RCI Hospitality) with margin expansions in retail (Signet +130 bps op margin) contrasting biotech pressures; capital returns strong via dividend hikes (Signet +20% to $0.35, Occidental +8% quarterly) and buyback expansions (News Corp $1B, Niagen to $20M). Clinical catalysts abound in healthcare (SELLAS REGAL 72/80 events, Humacyte Symvess launch), signaling near-term alpha, while non-healthcare financials show proxy governance focus. Portfolio-level: 12/45 filings with YoY revenue growth (avg +25% in biotechs), but 8/45 with SSS declines (avg -3.5%); sentiment mixed/neutral (70%), with healthcare bullish on trials/partners. Implications: Favor biotechs with milestones and cash runway >2yrs; monitor Nasdaq risks and Q2 catalysts for healthcare outperformance vs broader market weakness.

25 high priority 20 medium 45 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — March 18, 2026

Across 50 filings in the USA S&P 500 Consumer Staples stream (with broader exposure via related filings), proxy statements dominate, signaling peak AGM season in Q2 2026 with 10+ meetings (e.g., Wells Fargo April 28, Primo Brands April 28, Piedmont May 12), emphasizing governance and compensation votes amid stable sector backdrop. Financial reporters show robust revenue growth averaging ~30% YoY (e.g., Accelerant +51.5%, Five Below +22.9% FY25, Envela +33.6%), driven by expansion and M&A, but mixed profitability with margin compressions (Envela -220 bps, PGIM yield -122 bps) and swing losses (Accelerant -$1.35B). Staples highlights include General Mills earnings release and McCormick controller transition (neutral), while Primo Brands post-merger proxy underscores beverage stability. M&A/capital activity surges (FingerMotion acquisition, Energy Fuels ASM deal, Accelerant $200M buyback), but dilution risks in microcaps (Artelo bridge notes, ECD notes). Portfolio trends: 7/12 metric-rich filings report YoY revenue acceleration vs flat/decline in laggards like Actelis (-53%), positioning outperformers for catalysts. Implications: favor growth names with guidance (Five Below FY26 $5.2-5.3B sales), monitor proxies for comp changes, avoid dilution traps.

28 high priority 22 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — March 18, 2026

Across 50 filings from diverse sectors (heavy in financials despite Industrials focus), overarching themes include robust M&A activity in banking (e.g., Heritage Commerce merger supplements, Independent Bank $70M deal 6% accretive), mixed financial performance with revenue growth in outliers like Tecogen (+19.7% YoY to $27M) and Hills Bancorp (assets +4.5%, net income +27.1%), but margin pressures (Tecogen gross margins -730bps to 36.3%, Home Depot operating income -2.9%). Period-over-period trends show YoY revenue growth averaging ~10% in reporting firms (e.g., Spire FY25 $71.6M, Tecogen +20%), NIM expansions in banks (+67bps at Hills), but widening losses (Tecogen net loss +73% to $8.25M Q4) and flat incomes (Golden Growers +0.3%). Capital allocation leans toward dividends (Great Southern $0.43/share), debt extensions (Hilton RCf maturity extended), and equity issuances for M&A/growth. Critical developments: Advancing acquisitions (Great Lakes HSR cleared), positive guidance (Spire FY26 rev $75-85M, +41-61% ex-maritime), and leadership stability awards (Eagle Bancorp $1.175M continuity pay). Portfolio-level: Industrials subset shows resilient growth amid macro volatility, with M&A catalysts driving near-term upside but litigation risks in deals.

28 high priority 22 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — March 18, 2026

Across the six S&P 500 Energy stream filings (including contextual non-core like XOMA Royalty and Williams-Sonoma), key themes include robust capital allocation via dividends and buybacks, mixed financial performance with standout revenue growth in XOMA Royalty (+83% YoY to $52.1M) and Williams Companies (Adjusted EBITDA +9% YoY to $7.75B), contrasted by revenue declines at Williams-Sonoma (-4.2% YoY Q4 FY25). Period-over-period trends show strong YoY improvements in profitability for XOMA (net income $31.7M vs $13.8M loss) and operational expansions at Williams (12 growth projects completed, 10 announced), while Phillips 66 bolsters liquidity with a $2.25B term loan. Forward-looking catalysts cluster in 2026, including XOMA's Phase 2b volixibat data (Q2) and Phase 3 ersodetug (2H), Williams-Sonoma FY26 comps guidance (+2-6%), and Williams AGM on April 28. Energy-focused filers (Phillips 66, Williams) signal financial strength and growth conviction amid sector midstream/refining stability, but mixed sentiments highlight pipeline risks and margin pressures. Portfolio-level, 3/6 filings show dividend hikes (Williams +5%, Williams-Sonoma +15%), underscoring shareholder returns prioritization over reinvestment.

3 high priority 3 medium 6 total filings
· daily

S&P 500 Financials Sector SEC Filings — March 18, 2026

Across 50 SEC filings in the USA S&P 500 Financials intelligence stream (including banks, REITs, insurers, and adjacent sectors), overarching themes include robust capital returns via dividends (e.g., Great Southern Bancorp $0.43/share Q1 2026) and buybacks (Vistra $5.75B since 2021, NRG $1.65B), ongoing M&A activity in financials marred by shareholder litigation (Heritage-CVB merger supplements for 3 suits ahead of Mar 26 votes), and proxy approvals for governance amid neutral sentiment. Period-over-period trends reveal mixed revenue performance: 8/20 detailed reporters showed YoY growth averaging +38% (outliers TSS +66%, Bob's +16.8%), but 6 reported declines averaging -10% (Macy's -2.4% FY sales, Harte Hanks -13.9%), with margin compressions in 5/12 cases (-40bps avg, e.g., Macy's gross margin). Financials-specific patterns highlight REIT proxy focus on sustainability/insider policies (Seven Hills, ILPT) and bank merger risks, while forward-looking guidance flags upside (Protalix rev $78-83M 2026, Macy's Adj EPS $1.90-2.10). Critical developments: Strong 2025 beats (NRG EBITDA 167% target, Vistra Adj EBITDA +$112M), but going concern risks (Stardust $3.5M cash) imply selective opportunities in dividend payers and buyback leaders. Portfolio implications: Overweight financials with returns focus (avg dividend/buyback yield implied +5-7%), monitor Mar 26 bank votes for deal risks.

26 high priority 24 medium 50 total filings